AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia

Grant

Awarded By

Total Award Amount

  • 31100.00

    • Direct Costs

  • 24683.00

    • Sponsor Award Id

    • Contributor

  • Aman Wadhwa   Investigator  
  • Ana Xavier   Investigator  
  • Jeanine Dumas   Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Matthew Kutny M.D.   Principal Investigator